Bristol-Myers Squibb vs Unilever: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Unilever was founded in 1929 by William Hesketh Lever, Samuel van den Bergh, Anton Jurgens and is led by Fernando Fernandez.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Unilever
- Founded
- 1929
- Headquarters
- London, United Kingdom
- Current CEO
- Fernando Fernandez
- Employees
- 96,092
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Unilever
William Hesketh Lever
William Hesketh Lever (later Lord Leverhulme) co-founded Lever Brothers with his brother James in 1885 and built it around Sunlight Soap, one of the first branded, individually wrapped soaps sold at mass scale.
Samuel van den Bergh
Samuel van den Bergh led Van den Bergh, a Dutch margarine maker that became one of Jurgens' main rivals. The two families combined their businesses into Margarine Unie in 1927, and Margarine Unie merged with Lever Brothers in 1929 to create Unilever.
Anton Jurgens
Anton Jurgens' family firm was among the first to manufacture margarine commercially in the Netherlands after the product was invented in France. Jurgens competed for decades with the Van den Bergh family before the two merged into Margarine Unie in 1927.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Unilever
- Alan Jope2019–2023
Chief Executive Officer
Jope simplified Unilever's legal structure and organisation, which made later portfolio separations easier.
Source - Hein Schumacher2023–2025
Chief Executive Officer
Schumacher reset Unilever around fewer, bigger brands and set up the Ice Cream demerger before stepping down in February 2025.
Source - Fernando Fernandez2025–present
Chief Executive Officer
As CFO, the highly experienced Latin American executive enforces absolute financial discipline, attempting to restore investor confidence after years of sluggish stock performance.
Source
Timeline: Bristol-Myers Squibb and Unilever side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1884Unilever
Lever soap factory opens
William Hesketh Lever built the Port Sunlight soap business that became a key Unilever predecessor.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1929Unilever
Unilever created
Lever Brothers and Margarine Unie merged to form Unilever.
1929Unilever
Lever Brothers and Margarine Unie Merge
Lever Brothers and the Dutch Margarine Unie merged in 1929 to form Unilever.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1984Unilever
Acquired Brooke Bond
Unilever acquired Brooke Bond in 1984 for ~$515 million (£390 million).
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1989Unilever
Acquired Calvin Klein Cosmetics
Unilever acquired Calvin Klein Cosmetics in 1989.
1993Unilever
Acquired Breyers
Unilever acquired Breyers in 1993.
2000Unilever
Acquired Maille
Unilever acquired Maille. Unilever acquired Maille in 2000.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2019Unilever
Alan Jope becomes CEO
Alan Jope became CEO of Unilever in 2019. Jope simplified Unilever's legal structure and organisation, which made later portfolio separations easier.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020Unilever
Legal structure unified
Unilever moved to a single parent company structure after decades with British and Dutch holding companies.
2020Unilever
Single Parent Company
Unilever unified its dual structure into a single parent company, Unilever PLC, in November 2020.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Unilever
Fernando Fernandez becomes CEO
Fernando Fernandez was appointed CEO effective March 2025.
2025Unilever
Ice Cream demerger reflected
Unilever reported 2025 results on a continuing-operations basis after the Ice Cream business demerger.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Unilever
- Dr. Squatch2025Undisclosed
- Wild2025Undisclosed
- Minimalist2025Undisclosed
- Paula's Choice2021Undisclosed
- Sir Kensington's2017Undisclosed
- Weis2017Undisclosed
Questions about Bristol-Myers Squibb vs Unilever
Who is the CEO of Bristol-Myers Squibb Company and Unilever PLC?
Bristol-Myers Squibb Company is led by Christopher Boerner and Unilever PLC is led by Fernando Fernandez. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Unilever PLC?
Bristol-Myers Squibb Company was founded in 1887 — 42 years before Unilever PLC, which was founded in 1929. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Unilever PLC.
How many employees does Bristol-Myers Squibb Company have compared to Unilever PLC?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Unilever PLC employs approximately 96,092. Unilever PLC has the larger workforce at 96,092 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Unilever PLC headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Unilever PLC is headquartered in United Kingdom. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Unilever PLC?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Unilever PLC was founded by William Hesketh Lever, Samuel van den Bergh, Anton Jurgens.
Which company has a longer operating history — Bristol-Myers Squibb Company or Unilever PLC?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Unilever PLC has been in operation for around 97 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Unilever overview